Kenji Yoneda

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent.

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018, Investigative ophthalmology & visual science.

Glaucoma Pharmacologic Characterization of Omidenepag Isopropyl , a Novel Selective EP 2 Receptor Agonist , as an Ocular Hypotensive Agent

Naveed B K Shams, Noriko Odani-Kawabata, K. Yamamura, 2018 .

Antiplatelet action of R‐99224, an active metabolite of a novel thienopyridine‐type Gi‐linked P2T antagonist, CS‐747

H. Koike, T. Ogawa, K. Otsuguro, 2001, British journal of pharmacology.

Identification of the active metabolite of ticlopidine from rat in vitro metabolites

Sei Kobayashi, Y. Mizukami, H. Kishi, 2004, British journal of pharmacology.

UR-3216: a new generation oral platelet GPIIb/IIIa antagonist.

S. Tam, K. Baba, Y. Aga, 2004, Current pharmaceutical design.

Identification of a Selective, Non-Prostanoid EP2 Receptor Agonist for the Treatment of Glaucoma: Omidenepag and its Prodrug Omidenepag Isopropyl.

Naveed B K Shams, Noriko Odani-Kawabata, R. Iwamura, 2018, Journal of medicinal chemistry.

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells

Y. Sugimoto, Naveed B K Shams, Tomoaki Inazumi, 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, on Aqueous Humor Dynamics in Laser-Induced Ocular Hypertensive Monkeys.

M. Fuwa, C. Toris, Naveed B K Shams, 2018, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Pharmacokinetics, Safety and IOP Lowering Profiles of omidenepag isopropyl, a Selective EP2 Agonist in Healthy Japanese and Caucasian Volunteers (Phase I Study)

M. Aihara, Naveed B K Shams, Fenghe Lu, 2017 .

Omidenepag isopropyl, a selective EP2 agonist, shows additive intraocular pressure (IOP)-lowering effects when used concomitantly with existing anti-glaucoma drugs in animal models

Jin-Zhong Zhang, T. Taniguchi, M. Ichikawa, 2017 .

Safety and Efficacy of DE-117, a Selective EP2 Agonist in a Phase 2a Study

Naveed B K Shams, Fenghe Lu, R. Iwamura, 2015 .

Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells

M. Fuwa, Noriko Odani-Kawabata, R. Iwamura, 2023, PloS one.

Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys.

M. Fuwa, Naveed B K Shams, Noriko Odani-Kawabata, 2021, Journal of Ocular Pharmacology and Therapeutics.

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice

Naveed B K Shams, O. Katsuta, Noriko Odani-Kawabata, 2020, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.